CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: November 27, 2013
Result type: Reports
Project Number: SR0363-000
Product Line: Reimbursement Review

Generic Name: Mirabegron

Brand Name: Myrbetriq

Manufacturer: Astellas Pharma Canada Inc.

Therapeutic Area: Overactive bladder

Indications: Bladder, overactive

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 12, 2014

Recommendation Type: List with criteria/condition